Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia - PubMed (original) (raw)
Comparative Study
Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia
A J G Jansen et al. Transfus Med. 2004 Feb.
Abstract
Red-cell transfusions are required for symptomatic treatment of severe anaemia caused by intensive chemotherapy. Concerns about the transfusion-related complications, such as infections (e.g. the very low risk of human immunodeficiency virus (HIV)/hepatitis C virus (HCV) transmission and the risk of postoperative infections), haemolytic transfusion reaction, immunological effects and the costs, prompt a reevaluation of the transfusion practice. Retrospective analysis of prospectively collected data on 84 patients with acute myeloid leukaemia (AML), who were treated with combination chemotherapy between June 1, 1997 and December 7, 2001, was performed. The use of red-cell transfusions with a restrictive transfusion policy (haemoglobin = 7.2-8.8 g dL(-1), dependent on age and symptoms, n = 38) was compared with a more liberal transfusion trigger (haemoglobin = 9.6 g dL(-1), n = 46). The number of units transfused was recorded. Signs and symptoms of anaemia, chemotherapy-related effects and complications were investigated for both transfusion policies. The more restrictive transfusion policy led to a significant decrease of 11% of red blood cell (RBC) transfusions in patients with AML. No significant differences were found in the incidence of infections, number of platelet units transfused, bleeding complications, cardiac symptoms or response to chemotherapy. The more restrictive transfusion policy was feasible in this clinical setting, and it might be concluded that a restrictive transfusion policy is safe in supporting clinical patients treated with intensive chemotherapy for AML.
Similar articles
- A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation.
Webert KE, Cook RJ, Couban S, Carruthers J, Lee KA, Blajchman MA, Lipton JH, Brandwein JM, Heddle NM. Webert KE, et al. Transfusion. 2008 Jan;48(1):81-91. doi: 10.1111/j.1537-2995.2007.01485.x. Epub 2007 Sep 24. Transfusion. 2008. PMID: 17894791 Clinical Trial. - Reducing the red blood cell transfusion threshold from 8·0 g/dl to 7·0 g/dl in acute myeloid leukaemia patients undergoing induction chemotherapy reduces transfusion rates without adversely affecting patient outcome.
Ballo O, Fleckenstein P, Eladly F, Kreisel EM, Stratmann J, Seifried E, Müller M, Serve H, Bug G, Bonig H, Brandts CH, Finkelmeier F. Ballo O, et al. Vox Sang. 2020 Oct;115(7):570-578. doi: 10.1111/vox.12919. Epub 2020 Apr 28. Vox Sang. 2020. PMID: 32342521 - [Suitability of red blood cell transfusion: a multicenter study].
Gouëzec H, Berger E, Bergoin-Costello V, Betbèze V, Bourcier V, Damais A, Drouet N, Ducroz S, Fialon P, Hervé I, Huchet C, Lassale B, Léo S, Lovi V, Le Niger C, Moron S, Renom P, Delaunay C, Turmel V; Groupe des Hémobiologistes et Correspondants d'Hémovigilance. Gouëzec H, et al. Transfus Clin Biol. 2010 Dec;17(5-6):318-30. doi: 10.1016/j.tracli.2010.09.154. Epub 2010 Nov 4. Transfus Clin Biol. 2010. PMID: 21055992 French. - Should we reconsider triggers for red blood cell transfusion?
Hardy JF. Hardy JF. Acta Anaesthesiol Belg. 2003;54(4):287-95. Acta Anaesthesiol Belg. 2003. PMID: 14719346 Review. - Restrictive red blood cell transfusion strategies in critical care: does one size really fit all?
Nichol AD. Nichol AD. Crit Care Resusc. 2008 Dec;10(4):323-7. Crit Care Resusc. 2008. PMID: 19049485 Review.
Cited by
- How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology.
Prescott LS, Taylor JS, Lopez-Olivo MA, Munsell MF, VonVille HM, Lairson DR, Bodurka DC. Prescott LS, et al. Cancer Treat Rev. 2016 May;46:1-8. doi: 10.1016/j.ctrv.2016.03.010. Epub 2016 Mar 28. Cancer Treat Rev. 2016. PMID: 27046422 Free PMC article. Review. - Supportive care in patients with acute leukaemia: historical perspectives.
Cannas G, Thomas X. Cannas G, et al. Blood Transfus. 2015 Apr;13(2):205-20. doi: 10.2450/2014.0080-14. Epub 2014 Oct 23. Blood Transfus. 2015. PMID: 25369611 Free PMC article. Review. No abstract available. - Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation.
Berger MD, Gerber B, Arn K, Senn O, Schanz U, Stussi G. Berger MD, et al. Haematologica. 2012 Jan;97(1):116-22. doi: 10.3324/haematol.2011.047035. Epub 2011 Sep 20. Haematologica. 2012. PMID: 21933858 Free PMC article. - Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
Estcourt LJ, Malouf R, Trivella M, Fergusson DA, Hopewell S, Murphy MF. Estcourt LJ, et al. Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD011305. doi: 10.1002/14651858.CD011305.pub2. Cochrane Database Syst Rev. 2017. PMID: 28128441 Free PMC article. Updated. Review. - Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.
Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Pine AB, et al. Transfusion. 2017 Feb;57(2):289-295. doi: 10.1111/trf.13934. Epub 2016 Nov 22. Transfusion. 2017. PMID: 27878822 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources